Antibody Drug Conjugates and Drug Interactions
Antibody Drug Conjugates are highly potent biopharmaceutical drugs. They have been designed as a targeted therapy for the patients with cancer. They are complex molecules that have been composed of an antibody; it is a whole mAb fragment like a single-chain variable fragment [scFv]). We have seen that these Antibody drug conjugates are still at the initial stage of processing, but so far whatever a number of patients have used these drugs, positive feedback and results have so far been received. Here we will let you know about the processing of Antibody Drug Conjugates and their interaction with other drugs.
The Interaction of Antibody Drug Conjugates
They have unique targeting capabilities along with the cancer-killing ability. These antibody-drug conjugates let all the diseased tissue to be destroyed. If we compare it with the traditional chemotherapeutic agents, then we can say that these antibody-drug conjugates can well target and attack all the cancer cells. It has this capacity and ability to fight with this cancerous condition effectively.
How are Antibody Drug Conjugates combined with other antibodies?
Antibody Drug Conjugates are combined and coupled to an antibody so that it can precisely target a tumor marker. Antibodies trail these proteins right down in the body and then attach themselves to the surface of these cancer cells. Then a biochemical reaction takes place between the antibody and that target protein. As soon as ADC is internalized, that cytotoxic drug is then released and kills that cancer. It is seen that because of this targeting, that drug has few side effects, and it also gives you this option to have a wider therapeutic window as compared to other chemotherapeutic agents. These ADC technologies have been featured in many publications and also in the scientific journals.
Which of the ADCs has received market approval?
Three ADCs have received market approval from the U.S. Food and Drug Administration (FDA), first ADC got approval in 2001, and it was for the treatment of patients who had acute myelogenous leukemia. Then Brentuximab Bedouin was given approval by the U.S. Food and Drug Administration (FDA) in 2011. Trastuzumab emtansine was approved in February 2013, and it was for the treatment of people who had HER2-positive metastatic breast cancer.
Which of the ADCs are currently in clinical trials?
It has been seen that more than 30 ADCs have been currently in clinical trials and the majority of the ADCs have been currently under development for oncological and also for the hematological indications. It has been viewed that most of the drug developers have been seeking and looking to expand and extend the application of ADCs that will be beyond oncology and hematology. And this drug will then be used for another important disease too. Right now, these ADCs are at the initial and primary drug discovery stage, or you can say that they are at the preclinical stage of development, and many process and advancements have still and yet to come. Now, let us all see that when these Antibody drug conjugates will be given full approval.